ECOG-ACRIN Cancer Research Group

Congratulations to Dr. Bob Gray of @HarvardChanSPH @DanaFarber on his retirement as @eaonc Group Statistician! 🎉 We’re grateful for his many contributions to the #CancerResearch community. Wishing him all the best in this next chapter!

"Alcohol and tobacco use are known carcinogens. Treating alcohol and tobacco co-use can improve treatment and survivorship outcomes among patients diagnosed with cancer" EAQ171CD trial results: aacrjournals.org/cebp/articl…

Imaging-based swallowing assessment b4 surgery may help risk-stratify head and neck cancer patients for targeted support to mitigate swallowing morbidity. @BeatriceManduch @RaneeMehra & ECOG-ACRIN E3311 study team. sciencedirect.com/science/ar…

"Many large #hypertension trials excluded people with active cancer, leaving treatment goals unclear...ECOG-ACRIN EAQ191 was the first RCT in an active cancer population…" | Thank you authors & @SpringerNature for calling attention to this landmark trial! rdcu.be/3fEF9uBpfU8a

#ClinicalTrial EA3231, led by @LovaSunMD of @PennCancer, is testing #TargetedTherapy approaches for patients with #ThyroidCancer that has worsened during or after treatment. For more information: bit.ly/ea3231 #thycsm

Do you have early-stage #melanoma and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: bit.ly/ea6244-study #SkinCancer #MelanomaResearch

The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, & @theNCI, is testing new combinations of anti-cancer drugs, based on characteristics found in patients’ tumors or blood. Learn more: bit.ly/ComboMATCH #PrecisionMedicine

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial cc: @BladderCancerUS @JCensits @PGrivasMDPhD

Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for #ClinicalTrial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: bit.ly/ea1242-study cc: @NBCF, @SusanGKomen, @BCRFcure

Faster #ClinicalTrials. Greater patient participation. Quicker translation of scientific discoveries into better treatments. @NCIDirector shared his priorities for accelerating progress in #CancerResearch during a visit to @eaonc member @FoxChaseCancer: bit.ly/4zFaycy

Do you have #GastricCancer that has spread to the abdominal cavity? If so, you may be eligible to participate in this study of a potential new treatment approach. Learn more: bit.ly/ea2234-stopgap-ii #stomachcancer #cancerawareness

In #ClinicalTrial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal #sarcoma. More info: bit.ly/EA7211 Cc: @EORTC @richardriedelmd

#ClinicalTrial EA1241 is evaluating tissue samples from past TAILORx & RxPONDER trial participants who experienced a recurrence. This research aims to uncover why #BreastCancer returns after treatment. bit.ly/EA1241 cc: @jsparano, @KalinskyKevin, @RimapatelMD

Trial Activation: EA2251, led by Deirdre J. Cohen of @TischCancer @IcahnMountSinai, is a phase II/III randomized study of ivonescimab with gemcitabine and cisplatin versus standard of care #Chemoimmunotherapy in Advanced #BiliaryTract Cancer. More info: bit.ly/ea2251-study

#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/mm1oa-ea02-study #BloodCancer #leukemia

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: bit.ly/gable-trial

Do you have newly diagnosed #MultipleMyeloma and are either ineligible for or willing to delay #StemCell transplantation? If so, you may be eligible to participate in #ClinicalTrial EAA181/EQUATE. More info here: bit.ly/eaa181equate #MMSM #NDMM cc: @MM_Hub, @theMMRF

#ClinicalTrial EA8231, led by @MonikaJoshimd & @PGrivasMDPhD, is a phase 3 randomized study exploring a new treatment approach for patients with treatment-refractory, locally-advanced or metastatic #UrothelialCancer. More information here: bit.ly/ea8231-study

Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/indicate-trial #pcsm #ProstateCancerAware

#ClinicalTrial EA3231, led by @LovaSunMD of @PennCancer, is testing #TargetedTherapy approaches for patients with #ThyroidCancer that has worsened during or after treatment. For more information: bit.ly/ea3231 #thycsm